Recurrent Ovarian Cancer: When to Treat and How to Assess

Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer

“…7 The counterintuitive results of the OVO5/EORTC 55955 study led to a variety of criticisms about the trial and its conclusions, which have been vigorously defended. 8 Since the presentation of the OVO5/EORTC 55955 results, we have counseled patients at our institution about their follow-up at completion of their first-line chemotherapy. We have offered them 3 options for follow-up: (1) not to have routine CA125 measurements providing they are well and have no symptoms suggesting relapse, (2) to continue having routine CA125 measurements but not be told the result unless requested by the patient (particularly suitable for patients on clinical trials, where regular CA125 measurements are mandated), and (3) to have routine CA125 measurements and be told the results.…”

“… 7 The counterintuitive results of the OVO5/EORTC 55955 study led to a variety of criticisms about the trial and its conclusions, which have been vigorously defended. 8 …”